(NASDAQ: RGEN) Repligen's forecast annual revenue growth rate of 14.83% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 9.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.55%.
Repligen's revenue in 2025 is $633,513,000.On average, 7 Wall Street analysts forecast RGEN's revenue for 2025 to be $38,981,434,320, with the lowest RGEN revenue forecast at $38,325,081,236, and the highest RGEN revenue forecast at $39,245,040,061. On average, 3 Wall Street analysts forecast RGEN's revenue for 2026 to be $45,937,152,228, with the lowest RGEN revenue forecast at $44,073,815,408, and the highest RGEN revenue forecast at $47,118,475,725.
In 2027, RGEN is forecast to generate $56,091,155,734 in revenue, with the lowest revenue forecast at $56,091,155,734 and the highest revenue forecast at $56,091,155,734.